Quantum BioPharma is trading 10.05% down now at $3.31 as broader risk-off sentiment pressures speculative stocks.
- The Nasdaq Composite is down 1.35%, while the S&P 500 is down 0.65%.
- August 17, 2026, second-quarter results showed operating expenses down 53% year over year and approximately $9.5 million in liquidity, providing no clear negative company-specific catalyst.
- Recent FDA clearance for Lucid-MS Phase 2 was positive.